Alzheimer's Disease Clinical Trials 2024

What are the top hospitals conducting alzheimer's disease research?

In the quest to understand and combat Alzheimer's disease, several hospitals have emerged as leaders in pioneering clinical trials. The Boston Center for Memory, located in Newton, Massachusetts, leads the way with four ongoing trials focused on this debilitating condition. Over the years, they have conducted a total of 29 Alzheimer's disease trials since their first recorded study in 2010. Not far behind is Massachusetts General Hospital in Boston itself, where researchers are currently engaged in three active clinical trials for Alzheimer's disease. With a history dating back to 1995 when they embarked on their initial trial dedicated to this progressive disorder, they have accumulated an impressive tally of 29 completed studies.

Notably contributing to the field is NYU Langone Health based in New york City. Despite having only begun their journey into Alzheimer's research more recently with their first trial taking place in 2018, NYU Langone Health has already made significant strides by conducting three active clinical trials for this challenging condition while accomplishing nine previous studies.

Moving southward brings us to Brain Matters Research situated in Delray Beach—a hospital that has been at the forefront of Alzheimer's research since commencing its pioneering investigation back in 2003. Currently undertaking three active clinical trials for treating or managing symptoms associated with this neurodegenerative disorder; over time hitherto totaling sixty-eight diverse experiments—Brain Matters Research showcases its commitment towards advancing our understanding and treatment options regarding such conditions.

Lastly but no less importantly is Neuropsychiatric Research Center of Southwest Florida stationed within Fort Myers which also boasts an array of accomplished medical professionals actively working on three current alzheimer’s disease tests whilst possessing thirty-one previously-regarded investigations under its belt: theirs can be traced as far back simply twelve years ago until just ten years ago—an example reflective of relatively recent developments within scientific landscape

These hospitals serve not only as pillars offering hope to those affected by Alzheimer's but also exemplify how medical research and collaborative efforts are paving the way for innovative approaches to tackle this devastating disease. Each trial conducted, regardless of location or scale, contributes valuable knowledge in our collective fight against Alzheimer's and brings us closer to finding effective treatments and ultimately a cure.

Which are the best cities for alzheimer's disease clinical trials?

Miami, Florida; New york, New York; Toronto, Ontario; Indianapolis, Indiana; and Boston, Massachusetts are the top cities for Alzheimer's disease clinical trials. Miami leads with 18 active studies focused on Group A - Active Comparator, LY3372689, Simufilam, and other interventions. Following closely is New York with 11 ongoing trials investigating LX1001, DREEM 2 Headband, LY3372689,and more. Toronto and Indianapolis both have 10 active trials each exploring a range of treatments such as Nabilone,Dreem 2 Headband,Sinufilam,and others.Boston also offers significant opportunities for participation in Alzheimer's clinical research with its 8 active trials studying ADRD-PC Program ,Levetiracetam,Gamma,and others.These cities provide individuals affected by Alzheimer's disease access to cutting-edge clinical trials that drive progress towards effective treatments and improved quality of life.

Which are the top treatments for alzheimer's disease being explored in clinical trials?

Clinical trials are paving the way for new advances in Alzheimer's disease treatment. Among the top contenders, LX1001 has shown promise with two active trials and a total of two all-time trials dedicated to combating this debilitating condition since its introduction in 2019. Another contender is an intervention approach, which also boasts two active and two all-time Alzheimer's disease trials since its debut in 2016. Additionally, researchers are exploring the potential of blood-brain barrier (BBB) disruption as a treatment strategy, with ongoing investigations conducted through two active trials that began in 2018. Lastly, there is growing interest in supplemental oxygen therapy for Alzheimer's disease management, currently under investigation through one active trial initiated this year. These diverse avenues of research offer hope for breakthroughs on multiple fronts against Alzheimer's disease.

What are the most recent clinical trials for alzheimer's disease?

Exciting opportunities are emerging in the field of Alzheimer's disease research, as recent clinical trials shed light on potential breakthroughs. In one study, RB-ADSC low dose treatment is being investigated to address the challenges associated with this debilitating condition. Another trial focuses on BRIV Experimental, a promising therapy that has progressed from Phase 1 to Phase 2. Additionally, LX1001 showcases encouraging results in its Phase 1 stage for Alzheimer's disease patients. Furthermore, a unique Cardio-Dance Fitness intervention aims to enhance cognitive health and well-being in individuals affected by Alzheimer's disease during its Phase 2 evaluation. With these innovative trials collectively advancing our understanding and treatment options for Alzheimer's disease, there is renewed hope for improved quality of life for those impacted by this condition.

What alzheimer's disease clinical trials were recently completed?

Several recent clinical trials have made significant strides in the pursuit of improved treatments for Alzheimer's disease. Merck Sharp & Dohme LLC concluded their trial investigating MK-8189 in July 2022, while Alzamend Neuro, Inc. completed a trial for AL 001 in May 2022. Simultaneously, Virogenics, Inc.'s CMS121 study and TrueBinding, Inc.'s TB006 trial both wrapped up in May 2022 as well. These advancements join a list of other completed trials such as Acumen Pharmaceuticals' ACU193 (June 2021), T3D Therapeutics, Inc.'s 15mg T3D-959 (March 2021), and Axsome Therapeutics, Inc.'s AXS-05 (December 2020). Together with earlier studies by Athira Pharma (November 2020) and Mindful Diagnostics and Therapeutics LLC (November 2020) among others; they contribute to ongoing efforts to combat this challenging neurodegenerative condition.